- Home
- PSNL vs MRNS Comparison
PSNL vs MRNS Comparison
Compare PSNL & MRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSNL
- MRNS
- Stock Information
- Founded
- PSNL 2011
- MRNS 2003
- Country
- PSNL United States
- MRNS United States
- Employees
- PSNL N/A
- MRNS N/A
- Industry
- PSNL Medical Specialities
- MRNS Biotechnology: Pharmaceutical Preparations
- Sector
- PSNL Health Care
- MRNS Health Care
- Exchange
- PSNL Nasdaq
- MRNS Nasdaq
- Market Cap
- PSNL 321.1M
- MRNS 104.7M
- IPO Year
- PSNL 2019
- MRNS 2014
- Fundamental
- Price
- PSNL $5.19
- MRNS $0.31
- Analyst Decision
- PSNL Strong Buy
- MRNS Buy
- Analyst Count
- PSNL 4
- MRNS 12
- Target Price
- PSNL $6.81
- MRNS $4.56
- AVG Volume (30 Days)
- PSNL 439.4K
- MRNS 5.7M
- Earning Date
- PSNL 11-06-2024
- MRNS 11-05-2024
- Dividend Yield
- PSNL N/A
- MRNS N/A
- EPS Growth
- PSNL N/A
- MRNS N/A
- EPS
- PSNL N/A
- MRNS N/A
- Revenue
- PSNL $80,027,000.00
- MRNS $30,263,000.00
- Revenue This Year
- PSNL $10.85
- MRNS $21.18
- Revenue Next Year
- PSNL $8.77
- MRNS $56.42
- P/E Ratio
- PSNL N/A
- MRNS N/A
- Revenue Growth
- PSNL 19.20
- MRNS 16.56
- 52 Week Low
- PSNL $0.89
- MRNS $0.26
- 52 Week High
- PSNL $7.20
- MRNS $11.26
- Technical
- Relative Strength Index (RSI)
- PSNL 56.29
- MRNS 21.75
- Support Level
- PSNL $4.54
- MRNS $0.29
- Resistance Level
- PSNL $5.35
- MRNS $1.96
- Average True Range (ATR)
- PSNL 0.30
- MRNS 0.12
- MACD
- PSNL 0.05
- MRNS -0.18
- Stochastic Oscillator
- PSNL 84.71
- MRNS 2.41
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About MRNS Marinus Pharmaceuticals Inc.
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.